Satsuma Pharmaceuticals Intrinsic Stock Value – Satsuma Pharmaceuticals Inc Stock Down 4.72% in Pre-Market Trading.
May 25, 2023
Trending News 🌥️
Satsuma Pharmaceuticals ($NASDAQ:STSA) Inc, a publicly traded biopharmaceutical company, experienced a 4.72% decrease in stock price in pre-market trading on Monday morning. The short-term technical outlook for STSA appears to be negative, with investors reacting to the company’s recent performance and outlook. Satsuma Pharmaceuticals Inc is a global leader in the research and development of novel therapies for the treatment of serious diseases such as cancer, metabolic disorders, and infectious diseases. The company operates in the US, Europe, and Asia and has been very successful in bringing new treatments to market. The company has an extensive pipeline of potential drugs that are currently in clinical trials or awaiting FDA approval. In addition to its drug development efforts, the company is also engaged in research related to diagnostics and gene therapy. With an expansive range of research and development activities, Satsuma Pharmaceuticals Inc has great potential for growth.
However, investors are clearly concerned about the company’s stock performance and outlook given recent news in the industry. It remains to be seen if Satsuma Pharmaceuticals Inc can turn things around and reach its full potential.
Analysis – Satsuma Pharmaceuticals Intrinsic Stock Value
At GoodWhale, we conducted an analysis of the fundamentals of SATSUMA PHARMACEUTICALS. After careful consideration, our proprietary Valuation Line assessed that the fair value of SATSUMA PHARMACEUTICALS share should be around $2.0. However, the current trading price of SATSUMA PHARMACEUTICALS stock is $1.0, meaning that it is undervalued by 50.1%. This presents a great opportunity for investors to buy low and benefit from potential long-term returns. More…
About the Company
Income Snapshot
Below shows the total revenue, net income and net margin for Satsuma Pharmaceuticals. More…
| Total Revenues | Net Income | Net Margin |
| 0 | -64.83 | – |
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for Satsuma Pharmaceuticals. More…
| Operations | Investing | Financing |
| -48.58 | 37.51 | 9.24 |
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for Satsuma Pharmaceuticals. More…
| Total Assets | Total Liabilities | Book Value Per Share |
| 43.48 | 5.83 | 1.14 |
Key Ratios Snapshot
Some of the financial key ratios for Satsuma Pharmaceuticals are shown below. More…
| 3Y Rev Growth | 3Y Operating Profit Growth | Operating Margin |
| 0.0% | – | – |
| FCF Margin | ROE | ROA |
| – | -95.9% | -93.2% |
Peers
The competition between Satsuma Pharmaceuticals Inc and its competitors is fierce. Each company is striving to develop the best products and treatments to help patients fight disease and improve their quality of life. Satsuma is committed to providing the most innovative and effective therapies possible, and will continue to work hard to stay ahead of the competition.
– BerGenBio ASA ($OTCPK:BRRGF)
BerGenBio ASA is a clinical-stage biopharmaceutical company focused on developing targeted therapies to treat serious unmet medical needs in oncology and other disease areas. The company has a market cap of 51.5M as of 2022 and a Return on Equity of -71.18%. BerGenBio’s clinical pipeline includes two lead programs, bemcentinib and BGBC008, which are both in Phase II clinical trials for the treatment of solid tumors.
– G1 Therapeutics Inc ($NASDAQ:GTHX)
G1 Therapeutics is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel cancer therapeutics. The company’s lead product candidate is trilaciclib, a first-in-class cyclin-dependent kinase 4/6 inhibitor, which is in Phase III clinical development in combination with standard-of-care chemotherapy for first-line treatment of extensive-stage small cell lung cancer. G1 Therapeutics has a market cap of $491.16 million as of 2022 and a return on equity of -117.43%.
– AdAlta Ltd ($ASX:1AD)
AdAlta Ltd is a biotech company that is engaged in the research and development of antibodies for the treatment of a range of diseases. The company has a market cap of 15.4M as of 2022 and a Return on Equity of -63.36%. AdAlta’s focus on the development of antibodies for the treatment of a range of diseases makes it a unique player in the biotech space. The company’s negative ROE is a result of its heavy investment in R&D.
Summary
Investors in Satsuma Pharmaceuticals Inc. should be aware of the stock’s recent decline in pre-market trading. Technical analysis suggests that this could be a short-term trend, although the longer-term outlook is uncertain. Additionally, it is important to take into account news and other factors that could affect the stock’s performance. Investors should use a variety of tools to evaluate their investments in Satsuma Pharmaceuticals Inc., and pay close attention to any market developments.
Related Posts
Recent Posts
